Homegrown pharma major, Zydus Lifesciences Limited on Tuesday announced it has acquired UK-based LiqMeds Group of companies. The acquisition has been made through Zydus’ wholly-owned subsidiary, Zydus Pharmaceuticals UK Limited.
LiqMeds has capabilities and specialisation in development, manufacturing and supply of oral liquid products for global markets, which it currently commercialises through its partners.
The group’s subsidiary LM Manufacturing Limited (LMML), has an oral liquids manufacturing site at Weedon, Northampton, UK, which supplies products to the US and UK markets.
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on achievement of certain agreed milestones towards acquisition of the LiqMeds Group of companies.
The transaction will be EPS accretive for Zydus from the first year of acquisition.
Dr Sharvil Patel, managing director, Zydus Lifesciences Limited, said, “We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities. In line with our patient-centric approach, we believe that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance.”